Director/PDMR Shareholding

ConvaTec

12/03/2026 14:30

RNS Number : 4578W

Convatec Group PLC

12 March 2026

 

12 March 2026

Convatec Group Plc

("Convatec" or "the Company")

Director/PDMR Shareholding 

The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").

1.    Grant of Performance Share Awards

On 11 March 2026, the following conditional awards were granted to each of Jonny Mason, Chief Executive Officer and Fiona Ryder, Chief Financial Officer under the Convatec Group Omnibus Incentive Plan 2025 ("LTIP") in the form of Performance Share Awards ("PSA"). These PSA are due to vest on the third anniversary of grant at nil cost, conditional on the following performance conditions: organic revenue growth, three-year compound annualised growth in adjusted Earnings per Share, and three-year Relative Total Shareholder Return rank vs constituents of S&P Global Healthcare Equipment & Services index; and are subject to a two-year post vesting holding period:  

Jonny Mason:    1,776,206

Fiona Ryder:       567,413

2.    Grant of Deferred Bonus Awards

On the same date, the following conditional awards were granted to each of Jonny Mason and Fiona Ryder under the LTIP in the form of Deferred Bonus Awards ("DBA"). The DBA are due to vest on the third anniversary of grant at nil cost and are not subject to performance conditions:

Jonny Mason:    165,419

Fiona Ryder:       19,028

3.    Grant of Restricted Share Awards

On the same date, the following conditional awards were granted to each of Jonny Mason and Fiona Ryder under the LTIP in the form of Restricted Share Awards ("RSA"). The RSA are due to vest on the third anniversary of grant at nil cost and are not subject to performance conditions:

Jonny Mason:    417,931

Fiona Ryder:       170,224

The preceding three-day average share price, closing on 10 March 2026, of £2.4167 was used in determining each of the awards made under the LTIP.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Jonny Mason
2
Reason for the notification
a)
Position/Status
Chief Executive Officer and PDMR
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Convatec Group Plc
b)
LEI
213800LS272L4FIDOH92
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary share of 10p each in Convatec Group Plc
Identification code
GB00BD3VFW73
b)
Nature of the transaction
a. Grant of PSA under the LTIP, subject to performance conditions.
b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years.
c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
a.
£0
1,776,206
b.
£0
165,419
c.
£0
417,931
d)
Aggregated information
- Aggregated volume
- Price
2,359,556
£0
e)
Date of the transaction
2026-03-11
f)
Place of the transaction
Outside a trading venue

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Fiona Ryder
2
Reason for the notification
a)
Position/Status
Chief Financial Officer and PDMR
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Convatec Group Plc
b)
LEI
213800LS272L4FIDOH92
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary share of 10p each in Convatec Group Plc
Identification code
GB00BD3VFW73
b)
Nature of the transaction
a. Grant of PSA under the LTIP, subject to performance conditions.
b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years.
c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
a.
£0
567,413
b.
£0
19,028
c.
£0
170,224
d)
Aggregated information
- Aggregated volume
- Price
756,665
£0
e)
Date of the transaction
2026-03-11
f)
Place of the transaction
Outside a trading venue

 

 

 

Enquiries

James Kerton Company Secretary                                                                
 Email: cosec@convatec.com    

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation

About Convatec

 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHFLFEVVIIFLIR